NR4A1 and non-small cell lung carcinoma: If WFO can make targeted improvements to the treatment recommendations for patients with advanced cancer, non-small cell lung cancer, breast cancer with hormone receptor-positive and colorectal cancer with ECOG 1–2 or older (age > 70), it will be more suitable for clinical use in other countries.